SLC6A1 Gene

SLC6A1 Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SLC6A1 Gene</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>SLC6A1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>SLC6A1</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=SLC6A1" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

Gene Overview

SLC6A1 Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SLC6A1 Gene</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>SLC6A1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>SLC6A1</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=SLC6A1" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

Gene Overview

SLC6A1 (Solute Carrier Family 6 Member 1) encodes the GABA transporter 1 (GAT1), also known as GAT-1 or GAT1. This sodium- and chloride-dependent transporter is the primary mechanism for removing GABA from the synaptic cleft, terminating GABAergic signaling and maintaining precise temporal and spatial control of inhibition in the brain. GAT1 is essential for normal brain function, and its dysregulation has been implicated in epilepsy, Alzheimer's disease, Parkinson's disease, and various neuropsychiatric conditions["@borden1994"][@kanner1994].

The gene is located on chromosome 3p25.3 and encodes a 599-amino acid transmembrane protein with a molecular weight of approximately 67 kDa. GAT1 belongs to the neurotransmitter symporter family (SLC6), which includes transporters for dopamine, serotonin, norepinephrine, and other neurotransmitters.

Gene Structure and Protein

Genomic Organization

The human SLC6A1 gene spans approximately 25 kilobases on chromosome 3p25.3. The gene contains 16 exons that encode the GAT1 protein. Alternative splicing generates multiple transcript variants with tissue-specific expression patterns, though the predominant isoform is expressed throughout the brain[@borden1994].

GAT1 Protein Architecture

GAT1 is a member of the SLC6 family of Na⁺/Cl⁻-dependent neurotransmitter transporters. Key structural features include:

• 12 transmembrane domains (TM1-TM12): Hydrophobic alpha-helices that span the plasma membrane and form the translocation pore
• Intracellular N-terminus (residues 1-60): Contains regulatory serine and threonine residues that can be phosphorylated
• Intracellular C-terminus (residues 560-599): Contains PDZ-binding motifs and trafficking signals
• Extracellular loop 1 (between TM1 and TM2): Short connector with minimal glycosylation
• Large extracellular loop 2 (between TM3 and TM4): Contains N-linked glycosylation sites important for proper folding and trafficking
• Sodium binding sites: Two high-affinity Na⁺ binding sites (Na1 and Na2) required for transport
• Chloride binding site: Cl⁻ binding is required for transport activity and affects substrate affinity
• Functional unit: GAT1 forms a homodimer in the plasma membrane; dimerization is required for functional transport

Expression and Localization

Brain Distribution

GAT1 shows a characteristic pattern of expression in the central nervous system:

• Presynaptic terminals: High expression on GABAergic axon terminals, where it mediates GABA reuptake
• Astrocytes: Robust astrocytic expression, particularly in areas surrounding GABAergic synapses
• Neuronal cell bodies: Moderate expression in GABAergic interneurons
• Specific regions: Highest expression in hippocampus, cerebellum, and cerebral cortex

Cellular Localization

• Presynaptic membrane: Located on GABAergic nerve terminals
• Astrocytic processes: Ensheathes GABAergic synapses
• Axonal compartments: Distributed along axons of GABAergic neurons

Normal Function

Transport Mechanism

GAT1 catalyzes the Na⁺- and Cl⁻-dependent transport of GABA into presynaptic neurons and surrounding glial cells. The transport cycle proceeds through:

This electrogenic symport process uses the energy stored in the Na⁺ gradient to drive GABA transport against its concentration gradient[@kanner1994].

Physiological Roles

GAT1 is essential for normal brain function:

• Terminates synaptic transmission: Clears GABA from the synaptic cleft within milliseconds, ending GABAergic signaling
• Maintains GABA gradients: Ensures reliable replenishment of vesicular GABA stores
• Prevents spillover: Limits lateral diffusion of GABA to adjacent synapses, maintaining signal specificity
• Shapes inhibitory dynamics: Controls the duration and amplitude of inhibitory postsynaptic currents (IPSCs)
• Regulates tonic inhibition: Modulates extrasynaptic GABA concentrations that activate extrasynaptic GABA receptors

GABA-Glutamate Cycle

GAT1 participates in the GABA-glutamate cycle, an essential metabolic pathway in the brain:

This cycle ensures efficient recycling of both GABA and glutamate, the brain's primary inhibitory and excitatory neurotransmitters.

Role in Neurodegeneration

Alzheimer's Disease

GAT1 dysfunction contributes to AD pathogenesis through multiple mechanisms[@gastaldo2006][@czapski2017]:

GABAergic system decline: The GABAergic system deteriorates early in AD, contributing to network dysfunction and cognitive impairment. Loss of GAT1-mediated GABA clearance leads to:

• Altered excitation/inhibition balance
• Increased network excitability
• Impaired gamma oscillations important for cognition
• Greater susceptibility to seizures

• Elevated extracellular GABA
• Dysregulated inhibitory signaling
• Compensatory mechanisms that eventually fail

Parkinson's Disease

In PD, GAT1 plays important roles in basal ganglia function[@cheng2018]:

Basal ganglia circuitry: The basal ganglia rely heavily on GABAergic inhibition to control movement. GAT1 modulates:

• Striatal GABA levels
• Pallidal output
• Thalamic drive to cortex

• Abnormal plasticity at striatal synapses
• Dysregulated inhibition of movement circuits

• Oxidative stress response
• Excitotoxicity
• [Neuroinflammation](/mechanisms/neuroinflammation)

Epilepsy

GAT1 is critically involved in epilepsy pathophysiology[@carvill2015][@mathern1999][@richerson2005]:

GAT1 mutations: De novo mutations in SLC6A1 cause developmental and epileptic encephalopathy (DEE), characterized by:

• Early-onset seizures (often infantile spasms)
• Developmental delay
• Intellectual disability
• Refractory epilepsy

• Loss-of-function: Reduced GABA clearance → excessive inhibition followed by compensatory changes
• Gain-of-function: Enhanced GABA clearance → insufficient inhibition

Other Neurological Conditions

• Huntington's Disease: Reduced GAT1 expression in striatum contributes to GABAergic transmission deficits
• Tourette syndrome: GAT1 variants implicated in susceptibility
• Dystonia: GABAergic dysfunction involves GAT1
• Migraine: GAT1 may influence cortical spreading depression
• Anxiety disorders: GAT1 modulators show anxiolytic potential

Therapeutic Targeting

GAT1 Inhibitors

Several GAT1 inhibitors have been developed and some are in clinical use[@schousboe2004][@madsen2009]:

Clinical compounds:

• Tiagabine: FDA-approved for epilepsy, increases synaptic GABA by blocking GAT1
• Valnoctamide: In development, has GAT1 modulatory activity

• EF1502: GAT1/BET-CAT inhibitor with broad-spectrum activity
• NNC 711: Selective GAT1 antagonist
• SNAP-5114: GAT3-selective inhibitor

Therapeutic Applications

GAT1 modulation has potential in[@kaur2019][@dalby2003]:

• Epilepsy: GAT1 inhibitors reduce seizure frequency
• Anxiety: GABA enhancement has anxiolytic effects
• Insomnia: GAT1 modulators improve sleep architecture
• Neuropathic pain: GAT1 inhibition shows analgesic potential
• Cognitive enhancement: May improve cognition in AD by modulating network activity

Challenges and Side Effects

• Paradoxical effects: GAT1 inhibition can both treat and provoke seizures
• Network effects: Altering GAT1 affects entire networks, not just specific circuits
• BBB penetration: Many compounds have poor blood-brain barrier penetration
• Off-target effects: Lack of selectivity between GAT1, GAT2, and GAT3

• Tremor
• Dizziness
• Fatigue
• Weight gain
• Cognitive impairment (especially in elderly)

Interaction Network

GAT1 interacts with numerous proteins and participates in broader cellular networks:

• GABA: Primary substrate
• Sodium (Na⁺): Required co-transport ion (2 Na⁺ per GABA molecule)
• Chloride (Cl⁻): Required co-transport ion (1 Cl⁻ per GABA molecule)
• GAT2/SLC6A13: Functional overlap in some tissues, particularly in kidney and liver
• GAT3/SLC6A11: Primary glial GABA transporter, works in concert with GAT1
• Syntaxin 1A: Directly interacts with GAT1 N-terminus, regulates transporter trafficking
• PICK1: PDZ domain protein that clusters GAT1 at specific membrane domains
• NSF: Involved in recycling GAT1 from endosomes back to the plasma membrane
• PKC: Phosphorylates GAT1 at serine residues, modulates transport activity
• PKA: Modulates transport through second messenger pathways
• EAAT1/SLC1A3: Glutamate transporter that works in the GABA-glutamate cycle
• NSF: Involved in recycling
• PKC: Phosphorylates and regulates GAT1 activity
• PKA: Modulates transport activity

Genetic Variants

Known Variants

SLC6A1 genetic variants include:

• Missense variants: Several pathogenic variants identified in epilepsy patients
• Truncating variants: Cause loss-of-function
• Splice variants: Affect proper RNA processing
• Copy number variants: Deletions and duplications reported

Clinical Significance

• DEE association: SLC6A1 is a known cause of developmental and epileptic encephalopathy
• Population genetics: Carrier frequency is approximately 1 in 500 for some variants
• Genotype-phenotype: No clear correlation between variant type and phenotype

See Also

• [GABA Signaling](/mechanisms/gaba-signaling)
• [Inhibitory Neurotransmission](/mechanisms/inhibitory-neurotransmission)
• [GABA Receptors](/mechanisms/gaba-receptors)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Epilepsy](/diseases/epilepsy)
• [Huntington's Disease](/diseases/huntington-disease)
• [Excitotoxicity](/mechanisms/excitotoxicity)

External Links

• [NCBI Gene: SLC6A1](https://www.ncbi.nlm.nih.gov/gene/6529)
• [UniProt: P30531](https://www.uniprot.org/uniprot/P30531)
• [Ensembl: ENSG00000157103](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000157103)
• [GeneCards: SLC6A1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=SLC6A1)
• [IUPHAR: GAT1](https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=871)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving SLC6A1 Gene discovered through SciDEX knowledge graph analysis: